Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 1-year, Multicenter, Open-label Extension to CZOL446H2337 to Evaluate Safety and Efficacy of Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids

Trial Profile

A 1-year, Multicenter, Open-label Extension to CZOL446H2337 to Evaluate Safety and Efficacy of Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jul 2019

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Male osteoporosis; Osteoporosis
  • Focus Adverse reactions
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 04 Mar 2019 Status changed from active, no longer recruiting to completed.
    • 22 Feb 2019 Planned End Date changed from 15 Apr 2019 to 27 Feb 2019.
    • 22 Feb 2019 Planned primary completion date changed from 15 Apr 2019 to 27 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top